Chief Operating Officer
“We are driven, and have been right from the start, to find a way forward for creating cannabinoid based medicines, to validate the science and follow the gold standard medicines development approach, because the families we serve need them, and we work tirelessly to find a way for them.”
Chris Tovey is GW’s chief operating officer, a role he has held since joining the company in October 2012. He has over 30 years of commercial and operations experience in the pharmaceutical industry.
As COO, Chris is responsible for all international commercial activities beyond the US, manufacturing and supply chain, and information systems and security.
Prior to GW, Chris spent six years at UCB Pharmaceuticals in multiple roles, most recently as vice president of global marketing operations with responsibility for worldwide marketing activities on a product portfolio generating over $2B in annual sales, as well as managing director for Greece and Cyprus, and leader of the Business Unit responsible for the orphan narcotic medication Xyrem for the treatment of narcolepsy. Previously, he spent 18 years at GlaxoSmithKline in senior commercial roles, including director of commercial strategy for Europe distribution, director of the European vaccines therapy area, director of UK commercial development and director of the UK vaccines business. During his tenure at GSK, Chris worked across a wide range of therapeutic areas, including infectious diseases, epilepsy, psychiatry, oncology, diabetes, respiratory and immunology. He started his career in pharmaceutical sales at Beecham Pharmaceuticals.
Chris holds a Bachelor of Science in marine biology from the University of Liverpool, UK.